Avalo Therapeutics, Inc.AVTXNASDAQ

Revenue (LTM)

$441000

-77.1% YoY

Net Income (LTM)

$-35M

-11.4% YoY

Free Cash Flow

$-49M

Revenue CAGR (5Y)

-49.3%

Marginsimproving

FCF($0.0B)

Unprofitable

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Revenue	7	5↓19.4%	18↑234.4%	2↓89.3%	0↓77.1%
Gross Profit	6	4↓38.9%	15↑274.1%	1↓95.6%	1↑26.1%
Operating Income	0	-82	-37↑54.4%	-27↑26.9%	-69↓150.5%
Net Income	-64	-84↓32.9%	-42↑50.6%	-32↑24.3%	-35↓11.4%
EBITDA	-45	-80↓77.1%	-37↑53.7%	-23↑37.5%	-68↓193.5%
EPS Diluted	-2523.77	-2330.66↑7.7%	-1062.65↑54.4%	-113.58↑89.3%	-3.26↑97.1%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Cash & Equivalents	19	55↑188.5%	13↓75.9%	7↓43.7%	135↑1714.5%
Total Current Assets	26	62↑137.8%	16↓73.5%	8↓48.9%	139↑1554.4%
Total Assets	44	80↑83.3%	33↓58.4%	21↓37.1%	151↑618.0%
Total Current Liabilities	15	20↑30.6%	22↑11.2%	5↓79.1%	7↑50.7%
Total Liabilities	19	57↑197.7%	44↓22.5%	14↓69.1%	18↑29.3%
Total Equity	25	23↓6.0%	-11↓147.3%	7↑166.9%	133↑1721.4%
Total Debt	0	33↑7721.1%	20↓40.1%	1↓97.3%	1↑5.8%
Net Debt	-18	-21↓15.0%	7↑131.9%	-7↓201.5%	-134↓1847.9%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Operating Cash Flow	-41	-71↓74.9%	-27↑62.3%	-31↓14.7%	-49↓59.9%
Capital Expenditure	-0	-0↓79.4%	-0↑15.9%	-0↓66.3%	0
Free Cash Flow	-41	-71↓74.9%	-27↑62.2%	-31↓14.9%	-49↓59.1%
Stock-Based Comp	7	8↑20.4%	8↓7.6%	3↓54.0%	6↑68.3%
Net Change in Cash	15	36↑132.5%	-41↓215.9%	-6↑86.1%	127↑2303.2%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance